Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

NCT07363252

Retrospective-prospective observational multicentric study including radically resected EGFR-mutated NSCLC patients relapsed during or after adjuvant osimertinib, received according to clinical practice

EGFR-mutated NSCLC

Gruppo Oncologico Italiano di Ricerca Clinica100 participantsStarted Apr 2026

Bari, BA, Italy • Bergamo, BG, Italy • Bologna, BO, Italy +22 more locations

TERMINATEDPhase 1

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

NCT05241873

This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.

Lung Neoplasm MalignantCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+17 more

Blueprint Medicines Corporation103 participantsStarted Mar 2022

Duarte, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +20 more locations

Data from ClinicalTrials.govTerms

Showing 1-2 of 2 trials

RECRUITING

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

NCT07363252

Retrospective-prospective observational multicentric study including radically resected EGFR-mutated NSCLC patients relapsed during or after adjuvant osimertinib, received according to clinical practice

EGFR-mutated NSCLC

Gruppo Oncologico Italiano di Ricerca Clinica100 participantsStarted Apr 2026

Bari, BA, Italy • Bergamo, BG, Italy • Bologna, BO, Italy +22 more locations

TERMINATEDPhase 1

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

NCT05241873

This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.

Lung Neoplasm MalignantCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+17 more

Blueprint Medicines Corporation103 participantsStarted Mar 2022

Duarte, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +20 more locations

Data from ClinicalTrials.govTerms

Filters

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations